Dysregulation of Tweak and Fn14 in skeletal muscle of spinal muscular atrophy mice
© 2022. The Author(s)..
BACKGROUND: Spinal muscular atrophy (SMA) is a childhood neuromuscular disorder caused by depletion of the survival motor neuron (SMN) protein. SMA is characterized by the selective death of spinal cord motor neurons, leading to progressive muscle wasting. Loss of skeletal muscle in SMA is a combination of denervation-induced muscle atrophy and intrinsic muscle pathologies. Elucidation of the pathways involved is essential to identify the key molecules that contribute to and sustain muscle pathology. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/TNF receptor superfamily member fibroblast growth factor-inducible 14 (Fn14) pathway has been shown to play a critical role in the regulation of denervation-induced muscle atrophy as well as muscle proliferation, differentiation, and metabolism in adults. However, it is not clear whether this pathway would be important in highly dynamic and developing muscle.
METHODS: We thus investigated the potential role of the TWEAK/Fn14 pathway in SMA muscle pathology, using the severe Taiwanese Smn-/-; SMN2 and the less severe Smn2B/- SMA mice, which undergo a progressive neuromuscular decline in the first three post-natal weeks. We also used experimental models of denervation and muscle injury in pre-weaned wild-type (WT) animals and siRNA-mediated knockdown in C2C12 muscle cells to conduct additional mechanistic investigations.
RESULTS: Here, we report significantly dysregulated expression of Tweak, Fn14, and previously proposed downstream effectors during disease progression in skeletal muscle of the two SMA mouse models. In addition, siRNA-mediated Smn knockdown in C2C12 myoblasts suggests a genetic interaction between Smn and the TWEAK/Fn14 pathway. Further analyses of SMA, Tweak-/-, and Fn14-/- mice revealed dysregulated myopathy, myogenesis, and glucose metabolism pathways as a common skeletal muscle feature, providing further evidence in support of a relationship between the TWEAK/Fn14 pathway and Smn. Finally, administration of the TWEAK/Fn14 agonist Fc-TWEAK improved disease phenotypes in the two SMA mouse models.
CONCLUSIONS: Our study provides mechanistic insights into potential molecular players that contribute to muscle pathology in SMA and into likely differential responses of the TWEAK/Fn14 pathway in developing muscle.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Skeletal muscle - 12(2022), 1 vom: 28. Juli, Seite 18 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meijboom, Katharina E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.08.2022 Date Revised 29.09.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13395-022-00301-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344227014 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344227014 | ||
| 003 | DE-627 | ||
| 005 | 20231226205046.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13395-022-00301-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344227014 | ||
| 035 | |a (NLM)35902978 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meijboom, Katharina E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dysregulation of Tweak and Fn14 in skeletal muscle of spinal muscular atrophy mice |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.08.2022 | ||
| 500 | |a Date Revised 29.09.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a BACKGROUND: Spinal muscular atrophy (SMA) is a childhood neuromuscular disorder caused by depletion of the survival motor neuron (SMN) protein. SMA is characterized by the selective death of spinal cord motor neurons, leading to progressive muscle wasting. Loss of skeletal muscle in SMA is a combination of denervation-induced muscle atrophy and intrinsic muscle pathologies. Elucidation of the pathways involved is essential to identify the key molecules that contribute to and sustain muscle pathology. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/TNF receptor superfamily member fibroblast growth factor-inducible 14 (Fn14) pathway has been shown to play a critical role in the regulation of denervation-induced muscle atrophy as well as muscle proliferation, differentiation, and metabolism in adults. However, it is not clear whether this pathway would be important in highly dynamic and developing muscle | ||
| 520 | |a METHODS: We thus investigated the potential role of the TWEAK/Fn14 pathway in SMA muscle pathology, using the severe Taiwanese Smn-/-; SMN2 and the less severe Smn2B/- SMA mice, which undergo a progressive neuromuscular decline in the first three post-natal weeks. We also used experimental models of denervation and muscle injury in pre-weaned wild-type (WT) animals and siRNA-mediated knockdown in C2C12 muscle cells to conduct additional mechanistic investigations | ||
| 520 | |a RESULTS: Here, we report significantly dysregulated expression of Tweak, Fn14, and previously proposed downstream effectors during disease progression in skeletal muscle of the two SMA mouse models. In addition, siRNA-mediated Smn knockdown in C2C12 myoblasts suggests a genetic interaction between Smn and the TWEAK/Fn14 pathway. Further analyses of SMA, Tweak-/-, and Fn14-/- mice revealed dysregulated myopathy, myogenesis, and glucose metabolism pathways as a common skeletal muscle feature, providing further evidence in support of a relationship between the TWEAK/Fn14 pathway and Smn. Finally, administration of the TWEAK/Fn14 agonist Fc-TWEAK improved disease phenotypes in the two SMA mouse models | ||
| 520 | |a CONCLUSIONS: Our study provides mechanistic insights into potential molecular players that contribute to muscle pathology in SMA and into likely differential responses of the TWEAK/Fn14 pathway in developing muscle | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Atrophy | |
| 650 | 4 | |a Denervation | |
| 650 | 4 | |a Fn14 | |
| 650 | 4 | |a Glucose metabolism | |
| 650 | 4 | |a Skeletal muscle | |
| 650 | 4 | |a Smn | |
| 650 | 4 | |a Spinal muscular atrophy | |
| 650 | 4 | |a Survival motor neuron | |
| 650 | 4 | |a Tweak | |
| 650 | 7 | |a Cytokine TWEAK |2 NLM | |
| 650 | 7 | |a RNA, Small Interfering |2 NLM | |
| 650 | 7 | |a Receptors, Tumor Necrosis Factor |2 NLM | |
| 650 | 7 | |a TWEAK Receptor |2 NLM | |
| 650 | 7 | |a Tnfrsf12a protein, mouse |2 NLM | |
| 650 | 7 | |a Tnfsf12 protein, mouse |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 700 | 1 | |a Sutton, Emma R |e verfasserin |4 aut | |
| 700 | 1 | |a McCallion, Eve |e verfasserin |4 aut | |
| 700 | 1 | |a McFall, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Anthony, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Kubinski, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Tapken, Ines |e verfasserin |4 aut | |
| 700 | 1 | |a Bünermann, Ines |e verfasserin |4 aut | |
| 700 | 1 | |a Hazell, Gareth |e verfasserin |4 aut | |
| 700 | 1 | |a Ahlskog, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Claus, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Kay E |e verfasserin |4 aut | |
| 700 | 1 | |a Kothary, Rashmi |e verfasserin |4 aut | |
| 700 | 1 | |a Wood, Matthew J A |e verfasserin |4 aut | |
| 700 | 1 | |a Bowerman, Melissa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Skeletal muscle |d 2012 |g 12(2022), 1 vom: 28. Juli, Seite 18 |w (DE-627)NLM215981456 |x 2044-5040 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:1 |g day:28 |g month:07 |g pages:18 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13395-022-00301-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 1 |b 28 |c 07 |h 18 | ||